Mounjaro: Dosing, Side Effects, Tracking

Quick Reference

• What it is: Tirzepatide, a dual GIP/GLP-1 receptor agonist
• What it treats: Type 2 diabetes (FDA-approved)
• How it's administered: Once-weekly subcutaneous injection via single-dose pre-filled pen
• Standard dosing range: 2.5 mg (initiation) to 15 mg (maximum maintenance)
• Needle: 31-gauge, 4 mm (hidden in pen)

Mounjaro is tirzepatide, a once-weekly injectable manufactured by Eli Lilly for type 2 diabetes management. FDA-approved in May 2022, it's the first dual GIP/GLP-1 receptor agonist to reach the market -- a genuinely new mechanism of action, not just another GLP-1 drug. In head-to-head trials against semaglutide, it produced larger reductions in both HbA1c and body weight. This page covers what you need to know as a patient: how the drug works, how to dose it, injection technique, side effects, monitoring, and tracking.

What Mounjaro Is

Mounjaro is the brand name for tirzepatide, a synthetic peptide that simultaneously activates two incretin hormone receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It comes as a single-dose, pre-filled pen -- one pen per injection, one injection per week.

There are six dose strengths, each in a color-coded pen:

Each monthly box contains 4 pens. During titration, your dose increases and your pen color changes every 4 weeks.

Mounjaro is not insulin and does not replace insulin therapy in patients who require it. However, it is frequently prescribed alongside metformin, SGLT2 inhibitors, and in some cases basal insulin.

How It Works

The dual agonist mechanism is what separates tirzepatide from semaglutide and other GLP-1-only drugs.

The GLP-1 pathway

GLP-1 receptor activation slows gastric emptying, stimulates glucose-dependent insulin secretion, suppresses glucagon release, and reduces appetite through central nervous system signaling. This is the same pathway that semaglutide (Ozempic, Wegovy) targets. It is well-characterized and well-understood.

The GIP pathway

GIP receptor activation adds several effects that GLP-1 alone doesn't produce:

• Enhanced insulin secretion: GIP is actually the more potent of the two incretins for stimulating insulin release in a glucose-dependent manner.
• Improved fat metabolism: Preclinical data suggests GIP receptor signaling affects how the body stores and mobilizes fat, particularly visceral fat.
• Complementary appetite effects: GIP signaling appears to amplify the satiety effects of GLP-1, producing greater appetite reduction than either pathway alone.
• Beta-cell preservation: Early evidence suggests the dual signal may support pancreatic beta-cell function over time, though long-term human data is still accumulating.

The combination of both pathways in a single molecule explains why tirzepatide produced greater HbA1c and weight reductions in trials than semaglutide alone. It's not simply "more" of the same signal -- it's a qualitatively different metabolic intervention.

For a full breakdown of the tirzepatide mechanism and trial data, see our tirzepatide guide.

Approved Uses

Mounjaro is FDA-approved for one indication:

Type 2 diabetes mellitus -- to improve glycemic control as an adjunct to diet and exercise.

Mounjaro is not FDA-approved for weight management. That indication belongs to Zepbound, which contains the same tirzepatide molecule. Prescribers sometimes use Mounjaro off-label for weight loss, but insurance will typically deny coverage for non-approved indications.

Cardiovascular outcome trial data for tirzepatide (the SURPASS-CVOT program) is ongoing. As of this writing, tirzepatide does not carry a cardiovascular risk reduction indication, unlike semaglutide (which demonstrated CV benefit in SUSTAIN-6 and SELECT).

Dosing

Mounjaro uses a gradual titration in 2.5 mg increments:

Not everyone escalates to 15 mg. Many patients achieve glycemic targets at 5, 7.5, or 10 mg. Your prescriber will assess your HbA1c, tolerability, and treatment goals at each level before deciding whether to increase.

The 2.5 mg starting dose is sub-therapeutic for most patients. Like semaglutide's 0.25 mg start, it exists to let your GI tract acclimate. Skipping it dramatically increases nausea and vomiting rates.

Dose timing: Inject the same day each week, any time of day, with or without food. If you need to change your day, ensure at least 3 days (72 hours) have passed since your last injection -- note this is different from semaglutide's 2-day (48-hour) minimum.

Missed dose: If fewer than 4 days (96 hours) have passed since your missed dose, take it as soon as possible. If 4 or more days have passed, skip it and resume on your next scheduled day. Do not double up.

Injection Sites and Technique

Mounjaro uses a single-dose pen with a hidden 31-gauge, 4 mm needle. You never see the needle, which reduces injection anxiety considerably.

Approved sites

• Abdomen: At least 2 inches from the navel. Most popular site for self-injection.
• Front of the thigh: Mid-thigh, anterior surface.
• Back of the upper arm: Easier with assistance. Difficult to self-inject with consistent technique.

Technique

1. Remove the pen from the refrigerator. Let it sit at room temperature for 30 minutes (reduces discomfort).
2. Inspect the pen -- the solution should be clear, colorless to slightly yellow, and free of particles.
3. Pull off the gray base cap.
4. Place the clear base flat against your skin at the injection site. Do not pinch the skin.
5. Unlock by turning the lock ring.
6. Press and hold the purple injection button. You'll hear a first click (injection starts), then a second click (injection complete).
7. Continue holding against the skin for a full 10 seconds after the second click.
8. Remove and discard the pen in a sharps container.

The pen delivers the full dose automatically. No dose dialing, no priming. If you release the button before the second click, you may not receive the full dose -- in that case, do not attempt to re-inject. Contact your prescriber.

Site rotation

Rotate each week. A straightforward system: alternate between abdomen (4 quadrants) and thighs (left and right) on a 6-week cycle. This gives each site at least 5 weeks of rest between uses.

See our GLP-1 injection site rotation guide for detailed rotation schedules.

Side Effects to Track

Common (from SURPASS trial data)

• Nausea: 12-18% depending on dose. Most pronounced in the first week after each dose increase. The titration schedule mitigates this significantly.
• Diarrhea: 12-17%. Tends to be self-limiting.
• Decreased appetite: 5-12%. Expected pharmacological effect.
• Vomiting: 5-9%. If persistent beyond the first week at a new dose, contact your prescriber.
• Constipation: 6-7%. Adequate fluid and fiber intake help.
• Dyspepsia: 5-8%. Usually mild.
• Abdominal pain: 5-6%.

In SURPASS-2, the rate of treatment discontinuation due to adverse events was 6-8.5% with tirzepatide (across doses) compared to 4.1% with semaglutide 1 mg. Most discontinuations were GI-related and occurred during dose escalation.

Less common but clinically significant

• Hypoglycemia: Uncommon when Mounjaro is used alone or with metformin. Risk increases significantly when combined with sulfonylureas or insulin. Your prescriber may reduce the dose of these medications when initiating Mounjaro.
• Gallbladder events: Gallstones and cholecystitis reported at higher rates than placebo, particularly with rapid weight loss.
• Pancreatitis: Rare but serious. Watch for severe persistent abdominal pain.
• Injection site reactions: Occasional erythema, pruritus, or swelling. Usually resolves without intervention.
• Allergic reactions: Rare. Seek immediate medical attention for facial swelling, breathing difficulty, or severe rash.

Boxed warning

Mounjaro carries the same class-wide boxed warning as GLP-1 drugs: thyroid C-cell tumors observed in rodent studies. Not confirmed in humans. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

What to Monitor

Bloodwork

• HbA1c: Every 3 months during titration, then at least every 6 months once stable. This is the primary efficacy measure. SURPASS-2 showed HbA1c reductions of 2.0-2.3% at the 10-15 mg dose levels.
• Fasting glucose: For interim monitoring. Particularly useful in the early weeks before HbA1c reflects the new treatment.
• Lipid panel: Baseline and every 3-6 months. Tirzepatide has shown favorable effects on triglycerides.
• Kidney function (eGFR, creatinine): Baseline and periodic. GI fluid losses can affect hydration and renal function.
• Liver enzymes (ALT, AST): Baseline recommended.
• Amylase/lipase: Only if pancreatitis is suspected.

Self-monitoring

• Blood glucose: Frequency depends on your full medication regimen. If you're on sulfonylureas or insulin, monitor more frequently during Mounjaro titration to catch hypoglycemia early.
• Weight: Weekly. Significant weight loss is expected even though Mounjaro's formal indication is diabetes -- the dual mechanism drives meaningful body weight reductions.
• Blood pressure: Monthly. Weight loss and metabolic improvement often lower BP, which may require antihypertensive adjustments.
• GI symptom log: Track what symptoms you have, when they occur relative to injection day, severity (1-10), and how long they last. This is the most actionable data your prescriber can use during titration.

Comparison to Alternatives

Mounjaro's primary advantage is potency: head-to-head against semaglutide 1 mg in SURPASS-2, tirzepatide at all doses produced superior HbA1c and weight reductions. The gap was particularly large at the 10 and 15 mg doses. The trade-off is a shorter track record -- Mounjaro has been on the market since 2022 versus 2017 for Ozempic, and it doesn't yet have cardiovascular outcome data.

Tracking Your Treatment

Mounjaro's titration has more dose steps than most GLP-1 drugs -- up to six dose levels over months of escalation. Tracking becomes essential when you're managing frequent dose changes, evolving side effects, and blood sugar that's changing in response to treatment.

What to log each week:

• Date and time of injection
• Dose level (track every escalation precisely)
• Pen color (a quick cross-check that you're using the right dose)
• Injection site and side
• Side effects within 72 hours, with severity and duration
• Fasting glucose readings
• Weight
• Next scheduled injection date

The 72-hour minimum between doses (if changing injection days) is different from semaglutide's 48-hour rule. Small details like this are easy to forget and important to get right. A tracking app eliminates the guesswork.

Done Dose handles tirzepatide's titration schedule natively. Set your starting dose, and the app tracks your escalation timeline, reminds you on injection day, logs your site rotation, and keeps your side effect history organized for prescriber visits.

Frequently Asked Questions

What is the starting dose for Mounjaro?

Mounjaro starts at 2.5 mg once weekly for the first 4 weeks. This is a tolerability dose. After 4 weeks, your prescriber will increase to 5 mg, with further escalation in 2.5 mg increments every 4 weeks up to a maximum of 15 mg, based on your glycemic response and tolerability.

How is Mounjaro different from Ozempic?

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Ozempic contains semaglutide, which only targets GLP-1 receptors. In head-to-head trials (SURPASS-2), tirzepatide produced greater HbA1c reductions and more weight loss than semaglutide 1 mg. They are fundamentally different molecules with different mechanisms.

What are the most common Mounjaro side effects?

Gastrointestinal symptoms dominate: nausea (12-18%), diarrhea (12-17%), decreased appetite (5-12%), vomiting (5-9%), and constipation (6-7%) depending on dose. These are most common during dose escalation and typically improve at each stable dose level.

Can Mounjaro be used for weight loss?

Mounjaro is FDA-approved only for type 2 diabetes. For weight management, the same molecule (tirzepatide) is sold as Zepbound. Your prescriber may prescribe Mounjaro off-label for weight loss, but insurance coverage for this use varies.

How do you inject Mounjaro?

Mounjaro uses a single-dose, pre-filled pen with a hidden 31-gauge, 4 mm needle. Place the pen flat against your injection site (abdomen, thigh, or back of upper arm), unlock the pen, press and hold the injection button until you hear two clicks, then hold for 10 seconds before removing.

Sources

1. Frias JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." The New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2107519
2. Rosenstock J, et al. "Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1)." The New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2108269
3. Eli Lilly and Company. "Mounjaro (tirzepatide) Prescribing Information." uspl.lilly.com/mounjaro
4. U.S. Food and Drug Administration. "FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes." fda.gov
5. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." The New England Journal of Medicine, 2022. DOI: 10.1056/NEJMoa2206038

Done Dose tracks your Mounjaro titration from 2.5 mg through 15 mg -- injection dates, site rotation, side effects, and glucose readings all in one place. Download Done Dose to stay on top of your protocol.